Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## QTI Price Partially Recovers to $2.88 While Query Surge Signals Deepening Scrutiny
Since the August 1 observation logged the stock at $2.69, QTI has partially recovered to $2.88 — a 7% bounce that partially offsets the prior 23% drawdown from $3.50 at inaugural coverage. What stands out more sharply is the AI query trajectory: Origin has now recorded 334 all-time queries, up from 236 at the last observation — a 42% increase in roughly two weeks. The acceleration is notable. The first interval (July 17 to August 1) produced 38 incremental queries; this interval produced 98. That inflection suggests the combination of price volatility and lack of public narrative is driving researchers to the filing layer directly, likely in search of going-concern language, capital structure details, or clinical pipeline status that management has not verbally contextualized. The filing signal structure remains completely unchanged across all three observations — risk_factor counts of 123, 96, and 96; strategic_event at 9 and 8; ai_adoption at 7, 7, and 6. Zero transcripts captured remains the defining analytical gap. The price bounce without any identifiable catalyst visible in the filing or transcript layer is worth noting: absent a captured earnings call or press release entering the system, this recovery cannot be attributed to information flow. Items to monitor: whether the query surge eventually converts into a transcript capture event, any amended filing or 8-K that shifts the signal counts, and whether the $2.88 level holds or the prior $2.69 low gets retested.
## QTI Price Partially Recovers to $2.88 But Query Surge and Persistent Transcript Silence Deepen the Analytical Gap
Since the August 1 observation logged QTI at $2.69, the stock has recovered approximately 7% to $2.88 as of August 14 — a modest bounce that still leaves the position 17.7% below the $3.50 opening coverage price from July 17. What is more notable than the price action is the acceleration in Origin query volume: from 198 at inauguration, to 236 two weeks later, to 314 today — a 33% jump in the most recent interval alone. That rate of acceleration suggests the price volatility itself is driving research activity, likely short-sellers, risk-screeners, or distressed-asset monitors rather than growth-oriented buyers, though without transcript data that inference remains speculative. The filing signal structure remains completely unchanged across all three observations — risk_factor counts of 123, 96, and 96; strategic_event counts of 9 and 8; ai_adoption counts of 7, 7, and 6. The immobility of these signals over nearly four weeks confirms no amended filing or supplemental disclosure has entered the system. Zero transcripts captured in three consecutive observations is now a pattern, not a gap — QTI is operating with no audible management voice in the public analytical record, which is itself a structural data point about investor relations posture. Key items to watch: whether the query acceleration (198 → 236 → 314) culminates in a filing trigger or price event that breaks the static signal pattern, any 8-K activity that might precede a capital raise or partnership announcement, and whether the $2.88 level holds or the prior $2.69 low is retested.
## QTI Price Deterioration Accelerates With Zero Transcript Visibility and Unchanged Risk Footprint
Since the inaugural observation on July 17, QTI has declined from $3.50 to $2.69 — a 23% drawdown in roughly two weeks — while the filing signal structure remains entirely static. The risk_factor counts (123, 96, 96), strategic_event counts (9, 8), and ai_adoption counts (7, 7, 6) are identical to the prior observation, confirming no new 10-K or amended filing has entered the system. What has changed is price and query volume: AI queries on Origin have risen from 198 to 236 (a 19% increase), suggesting the price drop is generating incremental research interest rather than indifference. That the market cap now registers as a zero-dollar display threshold on Nasdaq is a formatting artifact of micro-cap rounding, but the directional signal is real — this stock is compressing. The continued absence of any earnings transcript (0 captured across both observations) remains the most analytically significant gap. A 23% price decline in a two-week window with no conference call, no investor day, and no audible management commentary creates an information vacuum. The 123 risk factor matches in the 10-K carry elevated weight in that vacuum — without management narration, the filing language stands alone as the primary interpretive frame. Key items to watch: whether the query spike (198 → 236) converts into any transcript capture event, what is driving the price compression absent visible news catalysts, and whether the $2.69 level corresponds to any identifiable support from the company's capital raise history or offering price anchors.
## QTI Opening Coverage: Micro-Cap Medical Imaging Company With Heavy Risk Disclosure Footprint
This is the inaugural observation for QT Imaging Holdings, Inc. (QTI), currently trading at $3.50 with a market capitalization registering below $1 billion on Nasdaq as of July 16, 2026. QTI operates in the medical imaging space, and the filing signal analysis from the latest 10-K immediately draws attention: risk_factor matches dominate the disclosure landscape with counts of 123, 96, and 96 across separate signal passes. This density of risk language is notably elevated for a company at this stage and warrants careful examination of what categories of risk — regulatory, clinical, financial, or operational — are driving that volume. Strategic event signals (9 and 8 matches) and ai_adoption signals (7, 7, and 6 matches) suggest the company is at minimum narrating a technology evolution story, though zero earnings transcripts have been captured to date, making it impossible to assess management's verbal framing of these themes. The 198 all-time AI queries on Origin indicates modest but real investor and analyst curiosity around this name. The absence of any transcript record is a meaningful gap — it prevents cross-referencing what management says publicly against what the filings disclose structurally. Key items to watch: the specific composition of those 123 risk factor matches (clinical trial status, FDA pathway, going-concern language), whether any earnings calls or investor presentations get captured to triangulate the ai_adoption narrative, and whether the strategic event signals correspond to partnership activity, regulatory milestones, or capital raises.